Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Travoprost Ophthalmic Solution".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the US FDA for Travoprost Ophthalmic Solution. Travoprost is a generic medication used to treat glaucoma and ocular hypertension. A final approval means the company can now manufacture and commercially sell this product in the United States. This adds to Alembic's existing portfolio of US-approved ophthalmic products. The US generic pharma market represents a significant revenue opportunity, though exact commercial impact will depend on market dynamics and competition.
Positive for Alembic's US business growth and revenue diversification, as final USFDA approval enables commercial launch of this ophthalmic product. Supports the company's expansion in the US generic market, though near-term stock impact may be limited as such approvals are often anticipated.